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Abstract:  
Background: Type 2 diabetes mellitus (T2DM) is a global problem. Association of  multiple genes in T2DM becomes a hot 
point recently. This study was aimed to evaluate association of  vitamin D receptor gene polymorphisms with susceptibility to 
T2DM. 
Subjects and methods: One hundred T2DM Saudi male patients were included in this study and one hundred healthy Saudi 
men were used as control. For each individual, fasting blood glucose, cholesterol, HDL-C, LDL-C, HbA1c, insulin and 25-(OH) 
vitamin D were measured. In addition, Apal, BsmI and TaqI genotypes were performed for each subject. Data was analyzed by 
SPSS version 16, using Spearman's rho and ANOVA tests. 
Results: There was significant inverse correlation between 25-(OH) vitamin D level and T2DM (p<0.01). HbA1c was inversely 
correlated with 25-(OH) vitamin D level (P<0.05). Genotype study showed that tt of  TaqI genotype was higher in T2DM group 
compared with control group (p<0.05). Moreover, tt genotype has higher HbA1c than both TT and Tt genotypes (p<0.05). 
Conclusion: An association was confirmed between TaqI genotypes and T2DM but there is no correlation between BsmI, ApaI 
and T2DM. In addition, HbA1c is positively correlated with tt genotype of  TaqI.
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Background
Type 2 diabetes mellitus (T2DM) is still a global prob-
lem that affects individuals all over the world. Its prev-
alence in Saudi Arabia has increased in the last decade 
and affects the young at 30 years age1. T2DM prevalence 
and complications make it the first problem that affects 
Saudi’s life. It is characterized by insulin resistance and 
alteration in its secretion leading to disturbance in carbo-
hydrate, protein and lipid metabolism2. Both genetic and 
environmental factors influence T2DM development3. 
Vitamin D is responsible primarily for calcium hemosta-
sis but also involved in diverse types of  cells growth and 
differentiation4. Vitamin D deficiency enhances T2DM 
development and its supplementation induces glucose 
tolerance5. In non-obese diabetic mouse model, vitamin 
D plays important role in insulin release and normal glu-
cose tolerance6. Vitamin D exerts its effect through bind-
ing to specific intracellulareceptor called vitamin D re-
ceptor (VDR)7. The VDR is a member of  steroid/thyroid 
hormone receptor family which is expressed in different 
cells lines include pancreatic β-cell8. Vitamin D and VDR 
complex induce insulin secretion from pancreatic β-cells 
and this is may a procedure by which vitamin D induc-
es glucose tolerance9. The VDR gene is located at 12q13 
chromosome and many polymorphisms were indicated 
at this region. The most important polymorphisms are 
ApaI, TaqI and BsmI which covered by different studies in 
different area and ethics. The VDR gene polymorphisms 
become one of  the candidate genes that influence T2DM 
development10. Our previous study which was done on 
Saudi obese males showed an association between these 
polymorphisms and insulin resistance in these patients11. 
Accordingly, we aimed in this study to investigate the as-
sociation of  VDR gene polymorphisms and T2DM in 
Saudi population.
Subjects and methods:  
Subjects: This project consisted of  100 T2DM male pa-
tients enrolled from diabetic center of  King Abdul-Aziz 
specialist hospital in Taif  and 100 healthy males used as 
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control. Both groups matched in sex and ethics. All pa-
tients diagnosed according to the World Health Orga-
nization criteria (fasting blood glucose >126 mg/dL or 
2-hour postprandial blood glucose >200 mg/dL)12. The 
diagnosis was confirmed by answering the questioner 
constructed by authors of  this project that any patients 
in this study didn`t take any medications or vitamin sup-
plementation and didn`t suffering from any chronic that 
may alter vitamin D metabolism.All subjects in control 
group did not suffering from any chronic illness such as 
DM, hypertension, cardiac, hepatic, or urinary illness and 
did not use any medication affect vitamin D level. After 
an overnight fast, venous blood samples were collected in 
EDTA and plain tubes then separated immediately and 
stored at 4°C until the analysis.
Biochemical parameters: The plasma was used for 
biochemical marker measurement include glucose, tri-
glyceride, total cholesterol, HDL-C, LDL-C, insulin and 
25-(OH) vitamin D. Fasting blood glucose, triglyceride, 
cholesterol, HDL-C, LDL-C and HbA1c were measured 
in a Dimension autoanalyzer (Dade Behring Inc). Insulin 
and 25-(OH) vitamin D were measured by using ELISA 
technique13.
Genotyping: Blood samples collected in EDTA tube 
and the DNA was extracted from peripheral blood leu-
kocytes using the Thermo SCIENTIFIC DNA isolation 
kit (Thermo SCIENTIFIC). Genomic DNA was ampli-
fied and analyzed for VDR genotype by polymerase chain 
reaction (PCR) and restriction fragment length polymor-
phisms (RFLP) for, Apa1 Taq1 and BsmI genotypes using 
forward and reverse primers showed in Table 1.1. The 
PCR mix was contained 5 μL of  each primer (10 pmol), 
5 μL buffer, 1.5 μL MgCl2 (50 mM), 5 μL template DNA 
(50–100 ng), 5 μL dNTPs (2 mmol/L), Taq polymerase 
(MBI) 2 μL, H2O 26.5 μL. The DNA template was de-
natured at 95°C for 2 min. A total of  40 cycles of  PCR 
were performed, consisting of  denaturation step for 45 
sec at 94°C, an annealing step for 45 sec at optimum tem-
perature (67°C for ApaI/TaqI and 60°C for BsmI), and 
an extension reaction for 1 min at 72°C. A final extension 
step at 72°C for 2 min was added after the last PCR cycle. 
After amplification, the PCR products were digested by 
incubation with restriction enzymes. For ApaI polymor-
phism, the amplicon incubated with ApaI enzyme in 370C 
for 5 minutes to get its three genotypes on 1.5% agarose 
gel designated AA, Aa and aa. Incubation of  amplicon 
with TaqI at 650C for 4 hours produced TT, Tt and tt 
on 2.5% agarose gel. BsmI genotypes were produced after 
incubation of  amplicon with BsmI enzyme at 650C for 15 
min, then applied on 2% agarose gel14. The size of  each 
genotypes ApaI, TaqI and/span>BsmI are shown in Am-
plified Table 1 and Fig 1,2 and 3 respectively .
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Figure 1. Detection of Apa1 polymorphism 
by PCR-RFLP method. Lane 1 and 5: homozygote (AA), 
Lane 3: heterozygote (Aa), Lane 2 and 4: 
homozygote (bb).M is 100-bp DNA marker. 
 
 
 
Figure 2. Detection of Taq1 polymorphism by 
PCR-RFLP method. Lane 5 and 6: homozygote (TT), 
Lane 1 , 2 and 4: heterozygote (Tt), Lane 3 
homozygote (tt), M is 100-bp DNA marker. 
 
 
 
Figure 3. Detection of BsmI polymorphism 
by PCR-RFLP method. Lane 3: homozygote (BB), 
Lane 2 and 4: heterozygote (Bb), Lane 1: 
homozygote (bb). M is 25-bp DNA marker. 
Statistical analysis
Hardy–Weinberg equation was used to test whether the 
examined SNPs were in equilibrium. The SPSS software 
version 16 (SPSS Inc., Chicago, IL, USA) was used for 
statistical analysis. The correlations were tested using 
Spearman's rho. ANOVA was used in comparisons per-
formance. Both comparisons and correlations were con-
sidered statistically significant when p<0.05.
Results
The results were represented by Table 1, 2 and 3. Aver-
age of  population age, BMI, FBG, HbA1c, triglyceride, 
cholesterol, HDL-C, LDL-C, insulin and 2-(OH) vitamin 
D were represent in Table 2. Age, weight, BMI, FBG, 
HbA1c, triglyceride and insulin were significantly higher 
in T2DM patients compared with control group (P<0.01). 
Our focusing parameter 2-(OH) vitamin D showed a sig-
nificant higher level in T2DM group compared with con-
trol group (P= 0.003). Based on VDR genotypes, With 
respect to examined VDR SNPs, all examined genotypes 
were in Hardy-Weinberg equilibrium (Table 3). The result 
showed significant differences in TaqI in both groups.. 
The tt genotype was significantly more frequent in T2DM 
group than control group. The TT genotype of  Taq1 
was more frequent in control group than T2DM group. 
Moreover, the tt allele was more frequent in T2DM group 
while TT allele was more frequent in control group. The 
results were not confirmed any significant differences be-
tween T2DM group and control group in both BsmI and 
ApaI genotypes of  VDR (Table 3). 
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Table 1. Forward and reverse primers. 
 
SNP Sequences Restriction products (bp) 
  
Apa1 
  
  
  
Taq1 
  
  
  
BsmI 
  
  
  
Forward  5’-CAGAGCATGGACAGGGAGCAAG-3’ 
Reverse   5’-GCAACTCCTCATGGCTGAGGTCTCA-3’ 
  
  
Forward  5′-CAGAGCATGGACAGGGAGCAAG-3′ 
Reverse  5′- GCAACTCCTCATGGCTGAGGTCTCA-3′ 
  
  
Forward  5′-AGTGTGCAGGCGATTCGTAG-3′ 
Reverse  5′- ATAGGCAGAACCATCTCTCAG-3′ 
Allele AA: 740  Allele 
Aa: 740+515+225   
Allele aa: 515+225 
  
  
Allele TT: 495+245  Allele 
Tt: 495+290+ 245+205 
Allele tt: 290+245+205 
  
Allele BB: 360 
Allele Bb: 360+191+169 
Allele bb: 191+169 
 
 
 
  
Table 2. Comparison of biochemical parameters between type 2 diabetes mellitus 
patients and control using t-test (Mean±SD) 
 
P  value T2DM patients N= 100 
Control 
N= 100   
0.004** 38.25±10.36 25.25±6.30 Age   
0.001** 89.8±7.2 62.9±5.4 Weight (kg)   
0.003** 30.7±1.81 26.49±2.04 BMI   
0.002** 152.68±30.66 90.33±7.31 FBS (mg/dl) 
0.008** 183.59±33.49 158.44±21.22 TG (mg/dl) 
0.241 223.75±17.32 198.21±16.49 Cholesterol (mg/dL)   
0.566 47.65±5.01 51.96±7.73 HDL (mg/dL)   
0.311 123.91±22.56 102.32±9.44 LDL (mg/dL)   
0.004** 8.22±6.03 17.83±2.32 Insulin (pmol/L)   
0.003** 18.09±4.17 37.41±8.12 25-H-Vit-D (ng/mL)   
 
 
 
Table 3. Comparison of ApaI, TaqI and BsmI genotypes and allelic frequencies 
between type 2 diabetes mellitus patients and control 
 
Genotypes ApaI Control (100) % T2DM (100) % P value Hardy-
Weinberg P 
value 
AA 
Aa 
aa 
30 (30%) 
48 (48%) 
22 (22%) 
32 (32%) 
47 (47%) 
21 (21%) 
0689 
0.815 
0.809 
0.735$ 
Allele A 
Allele a 
108 (54%) 
92 (46%) 
111 (55.5%) 
89 (44.5%) 
0.665 
0.571 
  
Genotype TaqI         
TT 
Tt 
tt 
53 (53%) 
36 (36%) 
11 (11%) 
24 (24%) 
34 (34%) 
42 (42%) 
0.041* 
0.602 
0.013* 
0.208$ 
Allele T 
Allele t 
142 (71%) 
58 (29%) 
82 (41%) 
118 (59%) 
0.036* 
0.011* 
  
Genotypes BsmI         
BB 
Bb 
bb 
50 (50%) 
38 (38%) 
12 (12%) 
45 (45%) 
41 (41%) 
14 (14%) 
0.417 
0.632 
0.801 
0.263$ 
Allele B 
Allele b 
138 (69%) 
62 (31%) 
131 (65.5%) 
69 (34.5%) 
0.406 
0.558 
  
                         $: In Hardy-Weinberg equilibrium 
 
  
Table 1. Forward and reverse primers. 
 
SNP Sequences Restriction products (bp) 
  
Apa1 
  
  
Taq1 
  
BsmI 
  
Forward  5’-CAGAGCATGGACAGGGAGCAAG-3’ 
Reverse   5’-GCAACTCCTCATGGCTGAGGTCTCA-3’ 
  
Forward ′-CAG GCATGG CA GGAGCAAG-3′ 
Reverse  5′- GCAACTCCTCATGGCTGAGGTCTCA-3′ 
  
Forward  5′-AGTGTG AGGCGATTC TA -3′ 
Reverse  5′- ATAGGCAGAACCATCTCTCAG-3′ 
Allele AA: 740  Allele 
Aa: 740+515+225   
Allele aa: 515+225 
  
  
TT: 495+ 45  Allele 
Tt: 495+290+ 245+205 
Allele tt: 290+245+205
  
Allele BB: 360
Bb: 360+191+169
Allele bb: 191+169 
 
 
 
  
Table 2. Comparison of biochemical parameters between type 2 diabetes mellitus 
patients and control using t-test (Mean±SD) 
 
P  value T2DM patients N= 100 
Control 
N= 100   
0.004** 38.25±10.36 25.25±6.30 Age   
0.001** 89.8±7.2 62.9±5.4 Weight (kg)   
0.003** 30.7±1.81 26.49±2.04 BMI   
0.002** 152.68±30.66 90.33±7.31 FBS (mg/dl) 
8183.59±33.49 158 4 1.22 TG (mg/dl) 
0.241 223 75 17 321 8 21 16.49 Cholesterol (mg/dL)   
0.566 47.65±5.01 51.96±7.73 HDL ( g/dL)   
0.311 123.91±22.56 102.32±9.44 LDL (mg/dL)   
0.004** 8.22±6.03 17.83±2.32 Insulin (pmol/L)   
0.003** 18.09±4.17 37.41±8.12 25-H-Vit-D (ng/mL)   
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Table 4 represents a comparison of  all biochemical pa-
rameters between each genotype of  ApaI, TaqI and BsmI 
in all individual included in this study. The results showed 
a significant higher HbA1c value in tt genotype of  TaqI 
(P=0.029). According to BsmI genotypes, BB genotype 
showed a significant higher 2-(OH) vitamin D level 
(P=0.036)
Table 4. Comparison between fasting blood glucose, HbA1c, insulin and 25-(OH) 
vitamin D in each genotypes of ApaI, TaqI and BsmI in both groups 
 
ApaI genotypes AA Aa aa P value 
FBG 136.21±20.64 129.88±30.46 142.11±36.83 0.309 
HbA1c 7.99±2.08 8.12±3.22 8.33±2.06 0.752 
Insulin 18.03±4.36 20.45.03±6.36 19.79±5.36 0.601 
25-(OH) vit D 31.14±7.22 37.11±4.22 35.66±5.63 0.447 
TaqI genotype TT Tt tt P value 
FBG 140.24±28.01 126.44±35.19 125.34±21.79 0.335 
HbA1c 5.21±2.11 7.89±1.57 10.55±1.85 0.029* 
Insulin 17.26±4.04 21.69±7.28 24.81±2.36 0.466 
25-(OH) vit D 29.49±8.22 32.65±4.28 27.56±7.23 0.486 
BsmI genotype BB Bb bb P value 
FBG 111.20±20.21 120.66±18.93 133.67±30.51 0.298 
HbA1c 6.34±2.22 6.45±3.06 6.93±2.45 0.814 
Insulin 19.84±5.55 20.59±4.77 22.35±6.71 0.619 
25-(OH) vit D 40.21±3.22 38.58±5.92 37.73±4.44 0.671 
 
 
Discussion
Recently, T2DM affects young people and its complica-
tions are increased in Saudi Arabia. Vitamin D is steroid 
derived vitamin and has a large variety of  functions. It is 
involved in growth, bone strength, immune and nervous 
function. Low levels of  vitamin D can involve in develop-
ment of  various chronic diseases such as cancers, osteo-
arthritis and cardiovascular disease15. Vitamin D deficien-
cy is becoming a global problem in all countries including 
sunny areas. A study done by Alharbi et al., showed that 
98% of  all Saudi men included in their study have vita-
min D deficiency and this may occur as a result of  less 
exposure of  people to sun light due to high temperatures 
of  this area during spring, summer and autumn16. Sever-
al studies found that low vitamin D levels are associated 
with T2DM. Mercedes and his colleagues found that low 
vitamin D levels are associated with T2DM in Spanish 
people17. Also another study done by Romero and Lozano 
found that vitamin D deficiency is common in T2DM in 
patients in Southern Spain18. The results are in agreement 
with the previous studies, which showed that 97% of  
T2DM patients have vitamin D deficiency and the group 
has a lower level of  this vitamin compared with normal 
people. In 2017, Al-Hazmi and his colleagues also found 
that vitamin D deficiency is dominant in obese people11.  
also found that vitamin D deficiency is dominant in obese 
people11. In the same year, Mahmodenia et al., also found 
that vitamin D deficiency is common in obese and T2DM 
Iranian patients19. Both obesity and vitamin D insuffi-
ciency induce insulin resistance20. Vitamin D supplemen-
tation induces insulin production by pancreatic β-cells 
and It also improves insulin resistance and impaired glu-
cose tolerance in T2DM patients21. Vitamin D produces 
its signals either directly by binding to VDR in β-cells or 
indirectly by induction of  release of  calcium from these 
cells22. 
Several studies found inverse correlation between insulin 
level and 25-(OH) vitamin D level in T2DM patients23. 
This observation was not confirm in this study, but an 
inverse correlation between HbA1c and 25-(OH) vita-
min D was confirmed in this study as previous studies 
concluded24,25. Previously, several studies were done to 
evaluate association of  VDR with different chronic dis-
eases. Results of  previous studies to indicate association 
of  VDR genotypes and T2DM are conflict. In 2011, Reza 
et al found a significant difference in TaqI genotype be-
tween T2DM patients and control group in Iranian popu-
African Health Sciences Vol 19 Issue 4, December, 2019 2816
lation. Their result showed that TT genotype is decreased 
in T2DM patients group, but did not confirm any differ-
ence in TaqI allele26. Obesity is a predisposing factor for 
T2DM and previously, our group found that tt genotype 
of  TaqI  is more frequent in obese people11. Simlarly, 
this study showed that tt genotype of  TaqI is more fre-
quent in T2DM patients group. 
In addition, t allele is more frequent in T2DM patients 
group than control group. Other studied done on Turkish 
population found no association between TaqI genotype 
of  VDR and T2DM27. About ApaI genotype, Oh et. al., 
found that ApaI genotype is associated with T2DM in 
American population28. On the other hand, Dilmec et al 
found no association between this APaI genotypes and 
T2DM27. The finding also did not confirm association 
of  AqaI genotype and T2DM. Association between BsmI 
genotype and T2DM is reported by Speer et al., and Or-
tlepp et. al.,29,30. The study findings are inconsistent with 
those of  Mackawy et al who found no association be-
tween BsmI genotype and T2DM31. The reason for dif-
ferences in results of  studies that focus on association of  
VDR gene polymorphisms with T2DM may be due to 
genetic, ethical and environmental differences in popu-
lation. The strength of  this study was studying of  more 
than one genotype in vitamin D receptor and the subjects 
were matched in both race and sex. Moreover, The study 
demonstrated the correlation of  vitamin D genotypes 
with some diabetic parameters such as FBS, HbA1c, and 
insulin. The limitation of  this study was that it used dif-
ferent ages for T2DM patients.
Recommendation and conclusion
An association was confirmed between TaqI genotypes 
and T2DM but there is no correlation between BsmI, ApaI 
and T2DM among Saudi population. In addition, HbA1c 
is positively correlated with tt genotype of  TaqI. This is 
the first study done on Saudi population to evaluate as-
sociation of  VDR gene polymorphisms with T2DM. Vi-
tamin D supplementation is recommended to preventing 
insulin resistance and T2DM.
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